sample size of the GIPS-II trial was based on the results of the GIPS-I trial, it was not powered to demonstrate smaller benefits of GIK; however, not even a trend toward a therapeutic benefit was observed in our trial. Combined with the results of other trials, it can be concluded that, in the used regimen, GIK in adjunct to reperfusion therapy in STEMI patients does not lower mortality.
Previous reports on the effect of GIK in STEMI have been contradictory. The meta-analysis of Fath-Ordoubadi and Beatt (4) showed a benefit of GIK infusion; however, studies included in this meta-analysis were of older date, and none of the patients received reperfusion therapy. Most studies published after this meta-analysis only showed benefit of GIK in specific subgroups. The Estudios Cardiologicos Latinoamerica (ECLA) study demonstrated mortality reduction in the sub-group treated with reperfusion therapy (5). The Polish-GlucoseInsulin-Potassium (Pol-GIK) trial was prematurely stopped, because mortality was significantly higher in GIK patients (6) . The GIPS-I trial, including only patients treated with primary PCI, found a mortality reduction in patients without heart failure on admission (2) . The Clinical Trial of Reviparin and Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation (CREATE)-ECLA study, with a sample size of 20,201 patients, showed only a trend toward a better outcome in the patients (n ϭ 1,831) treated with primary PCI (7). The only study to date showing a clinical benefit of (glucose-) insulin was the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study; however, this study included hyperglycemic patients and was primarily aimed at reduction of glucose levels (8) .
There might be several explanations for the lack of effects of GIK in STEMI. Experimental evidence suggests a beneficial effect of GIK by shifting myocardial free fatty acid metabolism toward glucose metabolism. This is less oxygen-consuming and produces less toxic side products (1). Furthermore, reperfusion injury might be reduced by limiting apoptosis of post-ischemic myocardial cells; however, once adequate reperfusion has been established, GIK might be of limited value, because maximal myocardial salvage has already taken place. Furthermore, glycometabolic support might only be beneficial when it is aimed at lowering glucose levels in patients with severe derangement of glucose metabolism, as in the DIGAMI study (8) . In addition, side effects of GIK infusion include hyperglycemia, hyperkalemia, and fluid overload. This might diminish the potential benefits.
Although there is no role for GIK in routine practice of patients with STEMI, there remain several issues to be clarified. Administering concentrated GIK through a central line might diminish adverse effects of fluid overload. Starting GIK before reperfusion therapy, during ambulance transportation for example, and GIK regimens specifically aimed at euglycemia should be further investigated (8, 9) .
